Tapentadol Depot G.L. Pharma 150 mg Depottablett السويد - السويدية - Läkemedelsverket (Medical Products Agency)

tapentadol depot g.l. pharma 150 mg depottablett

g.l. pharma gmbh - tapentadoltartrat - depottablett - 150 mg - tapentadoltartrat 251,715 mg aktiv substans

Tapentadol Depot G.L. Pharma 250 mg Depottablett السويد - السويدية - Läkemedelsverket (Medical Products Agency)

tapentadol depot g.l. pharma 250 mg depottablett

g.l. pharma gmbh - tapentadoltartrat - depottablett - 250 mg - tapentadoltartrat 419,525 mg aktiv substans

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiska medel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Pioglitazone Teva Pharma الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

pioglitazone teva pharma

teva pharma b.v. - pioglitazonhydroklorid - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. efter initiering av behandling med pioglitazon, patienter bör ses över efter 3 till 6 månader för att bedöma svar på behandling (e. minskning i hba1c). hos patienter som misslyckas med att visa ett adekvat svar, pioglitazon bör avbrytas. i ljuset av potentiella risker med långvarig terapi, förskrivare bör bekräfta på senare rutin recensioner att dra nytta av pioglitazon upprätthålls.

Piperacillin/Tazobactam Midas Pharma 4 g/0,5 g Pulver till infusionsvätska, lösning السويد - السويدية - Läkemedelsverket (Medical Products Agency)

piperacillin/tazobactam midas pharma 4 g/0,5 g pulver till infusionsvätska, lösning

midas pharma gmbh - piperacillinnatrium; tazobaktamnatrium - pulver till infusionsvätska, lösning - 4 g/0,5 g - tazobaktamnatrium aktiv substans; piperacillinnatrium aktiv substans - piperacillin och enzymhämmare

Gentamicin Panpharma 40 mg/ml Injektions-/infusionsvätska, lösning السويد - السويدية - Läkemedelsverket (Medical Products Agency)

gentamicin panpharma 40 mg/ml injektions-/infusionsvätska, lösning

panpharma sa - gentamicinsulfat - injektions-/infusionsvätska, lösning - 40 mg/ml - gentamicinsulfat 67,8 mg aktiv substans

Paracetamol Panpharma 10 mg/ml Infusionsvätska, lösning السويد - السويدية - Läkemedelsverket (Medical Products Agency)

paracetamol panpharma 10 mg/ml infusionsvätska, lösning

panpharma sa - paracetamol - infusionsvätska, lösning - 10 mg/ml - glukosmonohydrat hjälpämne; paracetamol 10 mg aktiv substans - paracetamol

Midazolam Panpharma 1 mg/ml Injektionsvätska, lösning السويد - السويدية - Läkemedelsverket (Medical Products Agency)

midazolam panpharma 1 mg/ml injektionsvätska, lösning

panpharma sa - midazolam - injektionsvätska, lösning - 1 mg/ml - midazolam 1 mg aktiv substans - midazolam

Midazolam Panpharma 5 mg/ml Injektionsvätska, lösning السويد - السويدية - Läkemedelsverket (Medical Products Agency)

midazolam panpharma 5 mg/ml injektionsvätska, lösning

panpharma sa - midazolam - injektionsvätska, lösning - 5 mg/ml - midazolam 5 mg aktiv substans - midazolam

Trelema 50 mg + 100 mg + 150 mg + 200 mg Filmdragerad tablett السويد - السويدية - Läkemedelsverket (Medical Products Agency)

trelema 50 mg + 100 mg + 150 mg + 200 mg filmdragerad tablett

g.l. pharma gmbh - lakosamid - filmdragerad tablett - 50 mg + 100 mg + 150 mg + 200 mg - lakosamid 200 mg aktiv substans; lakosamid 150 mg aktiv substans; lakosamid 50 mg aktiv substans; lakosamid 100 mg aktiv substans